OncoPharm podcast

Dostarlimab's Journey in MMRd Rectal Cancer

22/10/2026
0:00
10:59
Manda indietro di 15 secondi
Manda avanti di 15 secondi
This week we take a (brief) stop back in time to the beginning of dostarlimab's journey that has ended (for now) in an accelerated approval for rectal cancer that is mismatch repair-deficient or high in micro-satellite instability (MMRd/h-MSI). Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Altri episodi di "OncoPharm"